Developing greener alternatives for industrial chemicals that have a smaller impact on the environment isn't always ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

In living organisms, protein molecules with different chemical structures called proteoforms, are produced from a single gene to perform a variety of physiological protein functions. It has been ...

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...

Merck gained Winrevair in its $11.5 billion acquisition of Acceleron in 2021 and got it across the FDA finish line in March of 2024 based on results from the phase 3 STELLAR trial.

MSD has put a stop to its Phase III HYPERION study investigating its pulmonary arterial hypertension (PAH) treatment Winrevair after the therapy provided positive results from another Phase III trial.

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study Merck (NYSE: MRK), known as MSD ...

The therapy, branded Winrevair, is already approved for treating the rare condition which causes high blood pressure in the lungs, leading to symptoms such as shortness of breath, chest pain and ...